GlassScriptPhysician profile
Akbar K Ahmed
NPI 1699908921
$3,495.75
in general payments reported to CMS, 2019-2025
19 companies · $2,427 in 2025
The $2,427 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $89.07 · 2021: $136 · 2022: $178 · 2023: $419 · 2024: $125 · 2025: $2,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,872 · Food and Beverage: $1,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,872.27 |
| Food and Beverage | $1,098.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,851.53 | 2019-2025 | Pascal, Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| W. L. Gore & Associates, INC. | $871.61 | 2025 | Gore Cardioform Asd Occluder, Gore Cardioform Septal Occluder |
| Terumo Medical Corporation | $176.76 | 2023-2024 | Metacross Otw, Glidewire, Heartrail |
| Abbott Laboratories | $116.07 | 2022-2025 | Perclose Prostyle, Amplatzer Amulet |
| Boston Scientific Corporation | $107.25 | 2019-2023 | Opticross |
| Novartis Pharmaceuticals Corporation | $64.75 | 2023 | |
| Cvrx, INC. | $48.40 | 2023 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $41.48 | 2022 | |
| Amgen INC. | $41.00 | 2022-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $34.00 | 2022-2023 | Farxiga |
| Kiniksa Pharmaceuticals, LTD. | $23.11 | 2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $20.32 | 2022 | |
| Merck Sharp & Dohme LLC | $18.24 | 2023 | Verquvo |
| Davol INC. | $15.60 | 2023 | Arista Ah Flexitip |
| Medtronic, INC. | $15.41 | 2024 | Linq II |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $14.06 | 2025 | Attruby |
| Bard Peripheral Vascular, INC. | $13.00 | 2020 | |
| Philips North America LLC | $12.78 | 2019 | |
| Cardiovascular Systems INC. | $10.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akbar Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.